At a recent event at the University of Akron School of Law, Professor Erika Lietzan spoke about what she called the “assault on drug patents,” including patent reform activity in Congress as well as proposals to prevent drug companies from patenting any changes or improvements to their drugs after approval (so called “one and done” proposals). She explained that medical…
Tag: Drug Manufacturing ⋅ Page 1
Professor Lietzan’s Research Analyzes Patent Terms for New Medicine
A recent article in Bloomberg Law, U.S. Patent System Crimps Drug Innovation for Toughest Diseases, looks at the research of Professor Erika Lietzan and Kristina M.L. Acri about how the development of new drugs is affected by the U.S. patent system. Their research will be published in a forthcoming article. Their empirical research looked at 642 approved drugs to determine…